XOMA Corporation (Nasdaq: XOMA) unveiled its interleukin-2 (IL-2) monoclonal antibody program, a series of novel agents from its scientific discovery ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News

XOMA (XOMA) Reports Q3 Loss of $2.08/ShareNovember 9, 2016 9:04 AM New XOMA Antibodies Unveiled at The Society for Immunotherapy of Cancer 31st Annual MeetingNovember 8, 2016 9:00 AM